Latest news
03.12.2020
Issuance of a 4th tranche of €1.5 million of notes convertible into new shares
DEINOVE immediately strengthens its cash position to finance the ongoing clinical trial testing DNV3837 for the treatment of severe...
19.11.2020
DEINOVE signs an Evaluation and Technology Development License with DSM
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that pioneers the application of biodiversity from the natural environment...
12.11.2020
DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020
Yannick Pletan to present the DNV3837 mechanism of action, key features of the antibiotic candidate and the protocol of the ongoing Phase...
Press Coverage
12.05.2020
Cdiff Foundation | A New Parenteral Treatment for a Severe C. difficile Infection
"A New Parenteral Treatment for a Severe C. difficile Infection" hosted by Nancy C. Caralla Join us with our two guests: Dr Yannick Pletan...
08.05.2020
Biotech & Finance | Alexis Rideau, arrive chez Deinove avec son réseau industriel et académique de pointe
C’est une nouvelle aventure pour Alexis Rideau, qui occupe depuis cette semaine la fonction de directeur général délégué de Deinove...
06.05.2020
La Tribune | Deinove recrute Alexis Rideau, nouveau DG délégué
Deinove, société montpelliéraine de biotechnologie développant des antibiotiques novateurs et des actifs biosourcés pour la cosmétique et...